{"id":11828,"date":"2019-02-25T11:45:40","date_gmt":"2019-02-25T10:45:40","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=11828"},"modified":"2019-02-25T11:45:42","modified_gmt":"2019-02-25T10:45:42","slug":"accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/","title":{"rendered":"Accordo Roche-Sparks Therapeutics. L’acquisizione vale 4,3 miliardi"},"content":{"rendered":"\n

photo by NeONBRAND <\/p>\n\n\n\n

Roche ha offerto 3,7 miliardi di euro (4,3 miliardi di dollari) per l’acquisizione di Spark Therapeutics, laboratorio specializzato in terapie genetiche. Con questa operazione, concretizzatasi in un accordo di fusione approvato all’unanimit\u00e0 dai CdA delle due aziende, Roche punta ai laboratori di Spark in materia di emofilia e di ricerca genetica. <\/p>\n\n\n\n

Le valutazioni del mercato della terapia genica in questi anni sono decisamente positive. Severin Schwan, CEO di Roche, afferma che \u201cl\u2019esperienza di Sparks in questo campo rappresenta una grande opportunit\u00e0 per trattare malattie complesse\u201d e fa cenno al nuovo programma sull\u2019emofilia A su cui la societ\u00e0 di Basilea sta puntando.<\/p>\n\n\n\n

Chiamato Spk-8011, tale programma dovrebbe entrare nella fase III di sperimentazione nel 2019 e seguire di pari passo il programma Spk-8016 (fase I\/II) sempre in ambito emofilico. La pipeline dell’azienda comprende anche un altro prodotto (Spk-9001) per il trattamento dell\u2019emofilia B e un altro contro la coroidemia (quest\u2019ultimo in fase I\/II). <\/p>\n\n\n\n

Inoltre, entro fine anno, dovrebbero giungere allo sviluppo clinico due soluzioni per far fronte alla ceroidolipofuscinosi neuronale di tipo 2 e alla malattia di Pompe. <\/p>\n\n\n\n


<\/p>\n","protected":false},"excerpt":{"rendered":"

photo by NeONBRAND Roche ha offerto 3,7 miliardi di euro (4,3 miliardi di dollari) per l’acquisizione di Spark Therapeutics, laboratorio specializzato in terapie genetiche. Con questa operazione, concretizzatasi in un accordo di fusione approvato all’unanimit\u00e0 dai CdA delle due aziende, Roche punta ai laboratori di Spark in materia di emofilia e di ricerca genetica. Le valutazioni del mercato della terapia genica in questi anni sono decisamente positive. Severin Schwan, CEO di Roche, afferma che \u201cl\u2019esperienza di Sparks in questo campo…<\/p>\n","protected":false},"author":297440,"featured_media":11829,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[],"class_list":["post-11828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"\nAccordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by NeONBRAND Roche ha offerto 3,7 miliardi di euro (4,3 miliardi di dollari) per l’acquisizione di Spark Therapeutics, laboratorio specializzato in terapie genetiche. Con questa operazione, concretizzatasi in un accordo di fusione approvato all’unanimit\u00e0 dai CdA delle due aziende, Roche punta ai laboratori di Spark in materia di emofilia e di ricerca genetica. Le valutazioni del mercato della terapia genica in questi anni sono decisamente positive. Severin Schwan, CEO di Roche, afferma che \u201cl\u2019esperienza di Sparks in questo campo...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-25T10:45:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-25T10:45:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Accordo Roche-Sparks Therapeutics. L’acquisizione vale 4,3 miliardi\",\"datePublished\":\"2019-02-25T10:45:40+00:00\",\"dateModified\":\"2019-02-25T10:45:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/\"},\"wordCount\":192,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/neonbrand-605156-unsplash-e1551091500413.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/\",\"name\":\"Accordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/neonbrand-605156-unsplash-e1551091500413.jpg\",\"datePublished\":\"2019-02-25T10:45:40+00:00\",\"dateModified\":\"2019-02-25T10:45:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/neonbrand-605156-unsplash-e1551091500413.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/neonbrand-605156-unsplash-e1551091500413.jpg\",\"width\":2000,\"height\":1333},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accordo Roche-Sparks Therapeutics. L’acquisizione vale 4,3 miliardi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/","og_locale":"en_US","og_type":"article","og_title":"Accordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners","og_description":"photo by NeONBRAND Roche ha offerto 3,7 miliardi di euro (4,3 miliardi di dollari) per l’acquisizione di Spark Therapeutics, laboratorio specializzato in terapie genetiche. Con questa operazione, concretizzatasi in un accordo di fusione approvato all’unanimit\u00e0 dai CdA delle due aziende, Roche punta ai laboratori di Spark in materia di emofilia e di ricerca genetica. Le valutazioni del mercato della terapia genica in questi anni sono decisamente positive. Severin Schwan, CEO di Roche, afferma che \u201cl\u2019esperienza di Sparks in questo campo...","og_url":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/","og_site_name":"Frezza Partners","article_published_time":"2019-02-25T10:45:40+00:00","article_modified_time":"2019-02-25T10:45:42+00:00","og_image":[{"width":2000,"height":1333,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Accordo Roche-Sparks Therapeutics. L’acquisizione vale 4,3 miliardi","datePublished":"2019-02-25T10:45:40+00:00","dateModified":"2019-02-25T10:45:42+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/"},"wordCount":192,"commentCount":0,"image":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg","articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/","url":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/","name":"Accordo Roche-Sparks Therapeutics. L'acquisizione vale 4,3 miliardi - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg","datePublished":"2019-02-25T10:45:40+00:00","dateModified":"2019-02-25T10:45:42+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/neonbrand-605156-unsplash-e1551091500413.jpg","width":2000,"height":1333},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/accordo-roche-sparks-therapeutics-lacquisizione-vale-43-miliardi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Accordo Roche-Sparks Therapeutics. L’acquisizione vale 4,3 miliardi"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/11828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=11828"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/11828\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/11829"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=11828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=11828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=11828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}